ImmuCell Corporation Loss Contingency, Receivable
ImmuCell Corporation (ICCC) had Loss Contingency, Receivable of $250.00 thousand as of 2023-09-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:LossContingencyReceivable · last filed 2025-08-14
- 2023-09-30: Loss Contingency, Receivable $250.00K.
| Period end | Loss Contingency, Receivable |
|---|---|
| 2023-09-30 | $250.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |